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ABSTRACT: In cancer cells, global genomic hypomethylation is found together with localized hypermethylation of
CpG islandswithin thepromoters and regulatory regions of silenced tumor suppressor genes.Demethylating agents
may reverse hypermethylation, thus promoting gene re-expression. Unfortunately, demethylating strategies are not
efficient in solid tumor cells. DNA demethylation is mediated by ten-eleven translocation enzymes (TETs). They
sequentially convert 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), which is associated with active
transcription; 5-formylcytosine; and finally, 5-carboxylcytosine. Although a-linolenic acid, eicosapentaenoic acid
(EPA), and docosahexaenoic acid, the major n-3 polyunsaturated fatty acids, have anti-cancer effects, their action, as
DNA-demethylating agents, has never been investigated in solid tumor cells.Here,we report that EPAdemethylates
DNA in hepatocarcinoma cells. EPA rapidly increases 5hmC onDNA, inducing p21Waf1/Cip1 gene expression, which
slows cancer cell-cycle progression. We show that the underlying molecular mechanism involves TET1. EPA si-
multaneously binds peroxisome proliferator-activated receptor g (PPARg) and retinoid X receptor a (RXRa), thus
promoting their heterodimer and inducing a PPARg2TET1 interaction. They generate a TET1-PPARg-RXRa pro-
tein complex,which binds to a hypermethylatedCpG island on the p21 gene,whereTET1 converts 5mC to 5hmC. In
an apparent shuttling motion, PPARg and RXRa leave the DNA, whereas TET1 associates stably. Overall, EPA
directly regulates DNA methylation levels, permitting TET1 to exert its anti-tumoral function.—Ceccarelli, V.,
Valentini, V., Ronchetti, S., Cannarile, L., Billi, M., Riccardi, C., Ottini, L., Talesa, V. N., Grignani, F., Vecchini, A.,
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DNAmethylation, a widely studied epigenetic modifica-
tion,playsmajor roles ingenomic stability,X-chromosome
inactivation, chromatin accessibility, nucleosome posi-
tioning, and gene expression (1, 2). During methylation,
DNA methyltransferases (DNMTs) catalyze a covalent
chemical reaction that adds amethyl group to the cytosine
ring carbon 5 position in CpG dinucleotides.
In most cancer cells, DNAmethylation is characterized
by global genomic hypomethylation and regional hyper-
methylation (3, 4). Global hypomethylation may activate
oncogenes and retrotransposons, imprinting loss and
chromosomal instability (5). On the other hand, regional
hypermethylation, at gene promoter and regulatory re-
gions on CpG islands, is one of the major mechanisms for
silencing tumor-related genes. DNA hypermethylation
is reversible, as demethylating agents can promote re-
expression of tumor suppressor genes (6). Although
demethylating agents, such as 5-azacytidine and 5-aza-29-
deoxycytidine (5-aza), are approved for therapeutic use in
some leukemic syndromes (7), demethylating strategies
are not particularly effective in solid tumor cells (8). Con-
sequently, the discovery of demethylating molecules that
are active in hepatocarcinoma cells (HCCs) could impact
greatly on epigenetic therapy (9).
Recent evidence showed that ten-eleven translocation
enzyme (TET)proteinsmediate activeDNAdemethylation
(10). Each TET family member (TET1, TET2, and TET3)
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is an oxoglutarate- and iron-dependent dioxygenase
that catalyses 5-methylcytosine (5mC) oxidation to
generate 5-hydroxymethylcytosine (5hmC) (11), which
is associated with active transcription (12). Sequen-
tial 5hmC oxidation generates 5-formylcytosine and
5-carboxylcytosine (13), both of whichmay be removed
by thymine DNA glycosylase. Alternatively, active
DNA demethylation may be promoted by 5hmC de-
amination, followed by base-excision repair. In fact,
TET protein dysregulation and 5hmC loss could lead
to carcinogenesis (14, 15).
In the human body, n-3 polyunsaturated fatty acids
(PUFAs) are primarily obtained from dietary sources (16),
as eicosapentaenoic acid (EPA) and docosahexaenoic
acid, 2 major n-3 PUFAs, are weakly synthesized from
a-linolenic acid (17). n-3 PUFAs have anti-cancer effects,
which are mainly related to modulation of membrane-
associated signal transduction, gene expression in can-
cer pathogenesis, and systemic inflammation (18, 19).
Moreover, n-3 PUFA eicosanoid derivatives, such as
prostaglandin (PG)E3 and other 3-series PGs, exhibit anti-
proliferative and anti-inflammatory activities that slow
tumor development (20, 21). PGE3 and other eicosanoid
metabolites were recognized as biomarkers that could
potentially mediate EPA anti-cancer activity (22).
The present study follows our previous work, which
reported that EPA acted as aDNAdemethylating agent in
leukemia cells (23, 24). Here, we explored in solid cancer
cells the molecular mechanism underlying EPA-related
DNA demethylation, an as-yet uninvestigated field. In
HCCs, we found that specific EPA binding to both per-
oxisome proliferator-activated receptor g (PPARg) and
retinoid X receptor a (RXRa) was the starting point for
inducing p21 expression, which then inhibited cancer cell-
cycle progression. In binding simultaneously to PPARg
and RXRa, EPA assembled the TET1-PPARg-RXRa pro-
tein complex, which reached DNA. There, TET1 induced
DNAdemethylation by enriching 5hmC in an exonic CpG
island, which, in turn, induced p21 gene transcription.
TET1 remained bound to DNA, whereas PPARg and
RXRa exited. These results exclude involvement of eicos-
anoidderivatives and establish that EPA itself functions as
a ligand for both receptors.
MATERIALS AND METHODS
Materials
Oleic acid (OA; 18:1, n-9), EPA (20:5, n-3), bovine serum albumin
(BSA) fractionV (fatty acid free), and 5-azawere purchased from
MilliporeSigma (Burlington, MA, USA).
Albumin-bound fatty acids
A stock solution of each fatty acid (5 or 10mM)was prepared, as
previously described (23). In brief, free fatty acid was diluted in
ethanol and precipitated by adding NaOH (final concentration:
0.25 M). The precipitate was dried under nitrogen, reconstituted
with 0.9% (w/v) NaCl, and stirred at room tempera-
ture for 10minwithdefattedBSA fractionV fatty acid free (final
concentration: 10% w/v) in 0.15 M NaCl. Each solution was
adjusted to pH 7.4 with NaOH and stored in the dark in ali-
quots at220°C under nitrogen. The fatty acid/BSAmolar ratio
was 4:1.
Cell culture and treatments
The rat hepatoma cell line McRH-7777 (CRL-1601) from Ameri-
can Type Culture Collection (Manassas, VA, USA) was cultured
inDMEMand supplementedwith 20%horse serum, 5% fetal calf
serum, 2 mM L-glutamine, and 1% penicillin/streptomycin at
37°C in a humidified incubator, aeratedwith 5%CO2. Cells were
seeded at a density of 0.33 106 cells/ml for all experiments. Cells
were incubated with fatty acid/BSA solutions and 5-aza at the
indicated concentrations and times.
Cell cycle and viability
RH-7777 cells were treated with 100 mM fatty acids and 1 mM
5-aza for 3, 24, and 48 h and analyzed by flow cytometry. After
washing and centrifuge at 200 g, cell pellets were resuspended in
1mlhypotonicpropidiumiodide (PI) solution (50mg/ml21 in1%
sodium citrate plus 0.1%TritonX-100;MilliporeSigma). Samples
were placed overnight in the dark at 4°C. The PI fluorescence of
individual nuclei was measured using an EPICS XL-MCL flow
cytometer (Beckman Coulter, Miami, FL, USA). The cell cycle
was analyzedbymeasurement ofDNA-boundPI fluorescence in
the orange-red fluorescence channel (FL2) through a 585/42 nm
bandpass filter with linear amplification. Distribution profiles
were analyzed using ModFit LT software (Verity Software
House, Topsham, ME, USA) to determine cell fractions in each
phase of the cell cycle (G0/G1, S, G2/M). At least 15,000 events
were collected for each sample. Cells were gated on FL2-area vs.
FL2-width plots to exclude aggregates and debris (25). Cell via-
bility after 3, 24, and48h fatty acid treatmentswasdeterminedby
counting triplicate samples for Trypan blue dye-excluding cells.
Quantitative RT-PCR
Total RNAwas extracted from control cells and after 3-, 24-, and
48-h treatmentswith 100mMfattyacids and1mM5-azausing the
Trizol reagent (Invitrogen S.r.l., Milano, Italy), according to the
manufacturer’s guidelines. Reverse transcriptionwas performed
using theQuanti Tect Reverse TranscriptionKit (Qiagen,Hilden,
Germany). Quantitative RT-PCR (qRT-PCR) was performed us-
ing the Mx3000P Real-Time PCR System with brilliant SYBR
Green qPCR Master Mix (Stratagene, San Diego, CA, USA) and
Rox as reference dye. qRT-PCR reactions were performed under
standardized conditions for each primer set.
Each time point was investigated with 4 replicates of
3 independent experiments for p21 (NM_080782 mRNA). The
primers were the following: forward, 59-AGTATGC-
CGTCGTCTGTTC-39; reverse, 59-CAAAGTTCCACCGTTC-
TCG-39. Rat hypoxanthine-guanine phosphoribosyltransferase
mRNA was the housekeeping gene. The DDCt method deter-
mined mRNA modulation (23).
Immunoblot analysis
RH-7777 cells were cultured in standard conditionswith 100mM
fatty acids or 1 mM 5-aza for 3, 24, and 48 h. Protein samples
(70 mg) from total cell lysates were subjected to SDS-PAGE, elec-
troblottedontoanitrocellulosemembrane (SchleicherandSchuell,
Keene, NH, USA), and probed with the following antibodies:
anti-p21, sc-6246 (Santa Cruz Biotechnology, Dallas, TX, USA);
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anti-TET1, sc-163446 (Santa Cruz Biotechnology); anti-TET2,
ab123816 (Abcam, Cambridge, MA, USA); anti-TET3, PA5-
34431 (Pierce, Dallas, TX, USA); anti-PPARg, PA3-821A
(Thermo Fisher Scientific, Waltham, MA, USA); and anti-RXRa,
ab28767 (Abcam). Immunoreactive bands were visualized using
the ECL assay (Amersham Pharmacia Biotech, Little Chalfont,
United Kingdom). Anti-b-Tubulin antibody (MilliporeSigma)
wasused tonormalize. Imageswere acquiredusing theVersaDoc
Imaging System (Bio-Rad, Hercules, CA, USA), and signals were
quantified using Quantity One software (Bio-Rad).
DNA isolation and p21 CpG island quantitative
DNA methylation
Genomic DNA from control RH-7777 cells or 100 mM OA or
EPA cells after 24 h treatment was extracted using FlexiGene
DNA Kit (Qiagen). European Molecular Biology Open Soft-
ware Suite (http://emboss.sourceforge.net/) and MethPrimer
(http://www.urogene.org/methprimer/) online software pro-
grams were used to identify potential CpG islands for the p21
gene. DNA methylation levels were quantified for rat p21
(MePH25981-3A; Qiagen) using the Methyl-Profiler qPCR
Primer Assay. Primers were designed by an optimized computer
algorithm to ensure that the amplicon contained cutting sites for
both methyl-sensitive and -dependent enzymes. The qRT-PCR
programwasperformedas instructed.DNAmethylation status of
CpG islands was determined using restriction enzyme digestion
(DNA Methylation Enzyme Kit MeA-03; Qiagen), followed by
SYBR Green-based qRT-PCR detection, as previously described
(23). The relative amount of each DNA fraction (methylated and
unmethylated) was calculated using the DCtmethod (23).
Bisulfite modification of genomic DNA
and sequencing
With the use of the FlexiGene DNAKit (Qiagen), genomic DNA
was obtained from RH-7777, control, or after 3, 24, and 48 h
treatment with 100 mM OA and EPA. The bisulfite reaction to
determine DNA methylation status was performed, as previ-
ously described (26). DNA fragments covering p21CpG islandV
(8021/8241)were amplified byPCRusing the followingprimers:
forward, 59-TTTGTGTTTTAGTTATAGGTATTATGTT-39; re-
verse, 59-AAATCTTAAACAACCCTAAACTCC-39. The PCR
productswere cloned into pCR2.1TOPO(Invitrogen S.r.l.), and 7
randomly picked clones from each of 2 independent PCRs were
sequenced using T7 primer at the Genechron-Ylichron Labora-
tory (Rome, Italy).
Methylation-specific DNA pyrosequencing analysis
DNA from RH-7777 cells was extracted using the FlexiGene
Kit (Qiagen), following themanufacturer’s instructions. DNA
bisulfite modification was performed using the EpiTect Plus
DNA Bisulfite Kit (Qiagen), according to the manufacturer’s
instructions. CpG island methylation, at a total of 163 CpG
sites within p21 intron 1 and exon 2, was analyzed in un-
treated controls and cells that had been treated with 100 mM
OA and EPA or 1 mM 5-aza, for 3, 24, and 48 h. Methylation
was quantified by pyrosequencing, a highly sensitive and
reproducible method that provides information for each CpG
site, using the PyroMark Q24 (Qiagen) platform. Specific
primers (Supplemental Table 1) were designed using Pyro-
markAssayDesign Software, v.2 (Qiagen) to analyze the 5p21
gene CpG islands. A standard pyrosequencing sample prep-
aration protocol was applied (27). Methylation at each CpG
site was determined from the C→T ratio by Pyromark Q24
Software (Qiagen). Methylation for each p21 island was
expressed as the mean percentage at all CpG sites.
Dot blot
Isolated DNA (1 mg/sample) was denaturated in 0.1 M NaOH
for 10min at 95°C andneutralizedwith 0.1 volNH4 acetate 6.6M
on ice. DNA samples were spotted on a Hybond N+ nylon
membrane (GE Healthcare, Little Chalfont, United Kingdom)
using a Bio-Dot apparatus (Bio-Rad). The membrane was cross-
linked at 120°C for 30min and blocked by 5% nonfatmilk for 1 h
at room temperature. It was then incubated overnight at 4°C in
0.2 mg/ml rabbit polyclonal anti-5hmC: 39791 (Active Motif,
Carlsbad, CA,USA), or 0.5mg/mlmousemonoclonal anti-5mC:
61479 (Active Motif). The blotted membrane was washed 3 3
10 min in Tris-buffered saline (TBS) + 0.1% Tween-20 and then
incubated for 1 h at room temperature with horseradish
peroxidase-conjugated goat anti-rabbit IgG (MilliporeSigma,
Burlington, MA, USA) or with horseradish peroxidase-
conjugated goat anti-mouse IgG (Thermo Fisher Scientific)
secondary antibodies in TBS + 0.1% Tween-20. The membrane
was then washed 33 10 min in TBS + 0.1% Tween-20 and visu-
alized by chemiluminescence with the SuperSignal West Dura
ExtendedDuration Substrate (Pierce). The equal-loading amount
of total DNA on the membrane was confirmed by staining with
0.02% methylene blue in 0.03 M sodium acetate (pH 5.2).
Hydroxymethylated DNA immunoprecipitation and
methylated DNA immunoprecipitation assays
Fragmented DNA (0.5 mg/sample; 200–1000 bp in size) was
denaturated for 10 min at 95°C. The hydroxymethylated DNA
immunoprecipitation (hMeDIP; P-1038-24; Epigentek, Farm-
ingdale, NY, USA) and methylated DNA immunoprecipitation
(MeDIP; P-2019-24; Epigentek) assays were performed, accord-
ing to the manufacturer’s instructions. Antibody buffer (100 ml)
was added to the following antibodies: 1 ml nonimmune IgG
(negative controls), 1 ml anti-5hmC, and 1 ml anti-5mC, and in-
cubated at room temperature for 60 min. After removing the
antibody buffer from the wells and washing with diluted
washingbuffer, 0.5mg fragmentedDNAwas added to eachwell.
After incubation for 90 min at room temperature on an orbital
shaker, the reaction wells were washed with diluted washing
buffer. Proteinase K was added for 15 min at 60°C, and the re-
action wells were incubated at 95°C for 3 min to inactivate the
enzyme. DNA samples were subject to qRT-PCR using Brilliant
SYBRGreenqPCRMasterMix. The followingprimerswereused
to amplify the island V sequence: forward, 59-CCCGGAACTG-
GAAGATTGT-39; reverse, 59-AGGTACTGGGCCTCTTGTCC-
39. Fold enrichmentwas calculated bymeans of the amplification
efficiency ratio of hMeDIP or MeDIP DNA samples over non-
immune IgG by using 2D(IgG Ct 2 sample Ct).
Chromatin immunoprecipitation (ChIP)
Using the EZ-ChIP Kit (MilliporeSigma), ChIP assays were per-
formed on ;20 3 106 RH-7777 cells or after 100 mM OA or EPA
treatment for 3, 24, and 48 h. Cellswere crosslinked and cell lysates
sonicated until chromatin fragments became 200–1000 bp in size.
Mouse RNA polymerase II (RNAPII) 8WG16 mAb MMS-
126R (Covance, Princeton, NJ, USA), rabbit TET1 09-872
(MilliporeSigma), goat TET2 ab123816 (Abcam), rabbit TET3
PA5-34431 (Pierce), mouse PPARg antibody (Abcam), and mouse
RXRa sc-2553 (Santa Cruz Biotechnology) were used for immuno-
precipitation (IP).Mouse IgG (Thermo Fischer Scientific), rabbit IgG
(MilliporeSigma), and goat IgG (Santa Cruz Biotechnology) were
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usedasnegative controls.After IP, recovered chromatin samples
were subjected to qRT-PCR with Brilliant SYBR Green qPCR
Master Mix. The following primers were used: forward,
59-CCCGGAACTGGAAGATTGT-39; reverse, 59-AGGTACTGG-
GCCTCTTGTCC-39. Datawere analyzed quantitatively according
to the formula 22D[Ct(IP) 2 Ct(input)]222D[Ct(control IgG) 2 Ct(input)] (28).
PPAR response element
Island Vwas analyzed for PPAR response element (PPRE) or its
variants using Dragon PPAR Response Element Spotted v.2.0
(Computational Bioscience Research Centre, Thuwal, Saudi
Arabia).
Co-IP assay
Nuclear extracts were prepared from RH-7777 cells after 24 h
EPA conditioning and were diluted with IP buffer (50 mM Tris-
HCl, pH8), 100mMNaCl, 5mMMgCl2, and 0.2%Nonidet P-40.
After incubation with Dynabeads Protein A (Thermo Fisher
Scientific), anti-PPARg PA3-820 (Thermo Fisher Scientific) was
added to the diluted nuclear extract. After overnight incubation,
the beads were washed with IP buffer, and IP proteins were
analyzedbyWesternblotting.Theantibodieswere the following:
PPARg PA3-821A (Thermo Fisher Scientific), TET1 sc-163446
(Santa Cruz Biotechnology), and RXRa ab28767 (Abcam).
PPARg (5 mg) was used per IP.
Immunofluorescence
Cell controls (23105) andcells after 3, 24, and48h treatmentwith
100mMOAandEPAwere cytospun for 4min at 400 rpm, rinsed
with ice-cold PBS, and fixed with 4% paraformaldehyde for
20 min at room temperature, followed by 1 h incubation with
blocking buffer (0.1% Triton X-100, BSA 3% in PBS). The cells
were subjected to immunofluorescence staining with mouse
5hmC HMC/4D9 (Epigentek; 1:300). Immunofluorescence for
5mC was performed as follows: after fixation with 4% para-
formaldehyde for 10 min, cells were permeabilized with 0.5%
Triton X-100 for 1 h and treatedwith 2NHCl for 45min at room
temperature. After blocking with PBS containing 0.1% Triton X-
100 and 1% BSA for 1 h, cells were incubated overnight at 4°C
with mouse 5mC 33D3 (Epigentek; 1:500) antibody. Cells were
thenwashedwith coldPBS, 3 times for 3min each, and incubated
at room temperature for 1 h with Alexa Fluor 488-labeled anti-
mouse secondary antibody (1:100; Thermo Fisher Scientific).
Nuclei were counterstained with DAPI (MilliporeSigma). Cell
fluorescence was analyzed using a Zeiss Axioplan fluorescence
microscope equipped with a Spot-2 cooled camera (Diagnostic
Instruments, Sterling Heights, MI, USA). Positive stained nuclei
were counted, and 10 fields from each experimental condition
were quantified and statistically analyzed using the Student’s
t test. Statistical significancewas acceptedwhenP, 0.05. Values
are presented as means6 SD.
5hmC immunofluorescence analysis, using dimethyloxallyl
glycine (DMOG; MilliporeSigma), investigated TET protein in-
hibition. Cells were cultured in DMEM complete medium and
treated for 4 h with 1 mM DMOG diluted in PBS buffer. After
DMOG, another sample was treated with 100 mM EPA for 3 h.
Proximity ligation assays
Cells (2 3 105 cells) were cytospun for 4 min at 400 rpm, rinsed
with ice-cold PBS, fixed with 4% paraformaldehyde for 20 min
at room temperature, and blocked with blocking buffer (0.1%
Triton X-100, BSA 3% in PBS) for 1 h at room temperature, which
also permeabilized the cells. Slides were immunostained at 4°C
overnightwith the following primary antibodies: goat anti-TET1
sc-163446 (Santa Cruz Biotechnology; 1:500), rabbit anti-PPARg
PA3-821A (Thermo Fisher Scientific; 1:200), mouse anti-PPARg
sc-7273 (Santa Cruz Biotechnology; 1:50), rabbit anti-EPA
PAO122Ge01 (Cloud-Clone, Houston, TX, USA; 1:100), and
goat anti-RXRa ab28767 (Abcam; 1:200). Duolink in situ prox-
imity ligation assay (PLA; MilliporeSigma) was performed,
according to the manufacturer’s protocol. In brief, PLA probe
solution and ligation-ligase solution were added for 1 h and
30min, respectively. The signalwas amplifiedwith amplification-
polymerase solution at 37°C for 100 min (Duolink in situ; Milli-
poreSigma). Nuclei were counterstained with DAPI. Slides were
analyzed using the Zeiss Axioplan fluorescence microscope,
equipped with a Spot-2 cooled camera (Diagnostic Instruments).
Positive-stained nuclei were counted, and 10 fields from each
experimental conditionwere quantified and statistically analyzed
using the Student’s t test. Statistical significance was accepted
when P, 0.05. Values are presented as means6 SD.
Statistical analyses
All results are presented as means 6 SD and were analyzed by
1-way ANOVA with Bonferroni’s post-test. A value of P, 0.05
was considered significant.
RESULTS
EPA inhibited cell-cycle progression and cell
viability and increased p21 expression in HCCs
As EPA acted as a demethylating agent in leukemia cells
(23, 24), we explored its action in several HCC lines.
RH-7777 rat HCCs emerged as an efficient experimental
model. We determined the effects of EPA on cell-cycle
distribution of the cells. After EPA treatment, the G0/G1
phase increased significantly in a concentration- and
time-dependent manner (Fig. 1A, B). OA, a monoun-
saturated fatty acid, had no effect under any of the study
conditions, confirming findings in leukemic cells (23)
(Fig. 1A, B). In 48 h , EPA conditioning induced 10–15%
cell apoptosis and was associated with a significant,
time-dependent reduction in cell viability (Fig. 1C).
p21Waf1/Cip1, a cyclin-dependent kinase inhibitor, is
encoded by the cyclin-dependent kinase N1A gene, ex-
pression of which is inversely related to cell-cycle pro-
gression (29). As decreased p21 expression leads to
excessive cell proliferation and cell-cycle dysregulation
inHCC (30), we examined p21mRNAand protein levels
after conditioning with EPA, OA, and 5-aza, a well-
knownDNA-demethylating agent (Fig. 1D–F). In 24 and
48 h, 5-aza treatment increased p21 mRNA and protein
expression. Surprisingly, 3 h EPA treatment significantly
increased p21 mRNA and protein expression, which
remained constantly high for up to 48 h. 5-aza and EPA
treatments seemed to act by different transcription
processes, as the kinetic profiles of p21 mRNA and
protein were similar (Fig. 1D, F). These findings indi-
cated that EPA and 5-aza decreased RH-7777 cell pro-
liferation and induced p21 expression. The very early
EPA-induced increase in p21 expression was the first
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step in transcription. It might have been a result of a
specific molecular mechanism, which decreased pro-
liferation and cell-cycle progression later in the 24 h
exposure.
Effects of EPA on the p21 gene CpG islands
To support the hypothesis that EPA promoted DNA
demethylation, we sought for CpG islands on the p21
gene. The sequence we analyzed (21000/+8459) con-
tained 1000 bp upstream to the transcription start site,
untranslated exon 1, intron 1, and exon 2 (Fig. 2A). Five
CpG islands were retrieved, hence forward-termed is-
lands I, II, III, IV, and V (Fig. 2A). Islands I–IV spanned
intron 1. The island V nucleotide sequence (Fig. 2B) was
located in an internal exon 2 region, adjacent to the ATG
(Fig. 2A).
Approximately 96% of p21 DNA copies were unme-
thylated in untreated HCCs. Methylation status did not
change after 24 h OA and EPA conditioning (Fig. 2C).
Seemingly, only a minimal part of DNA needs to be
methylated to reduce p21 gene expression. Methylation
levels for each CpG island (bisulfite-pyrosequencing
analysis) showed that in fact, only island V was methyl-
ated (Fig. 2D).
Bisulfite sequencing of islandV for single, selected, and
cultured clones showed that a few random CpGs were
demethylated after EPA treatment (Fig. 2E). This weak
CpG demethylation could not account for the strong in-
duction of p21 expression.
Interestingly, after EPA treatment, specific primers
(Supplemental Table 1) for island V pyrosequencing
analysis revealed that 18 CpG dinucleotides had not
changed their methylation levels (Fig. 2F, G). As expected,
5-aza conditioning decreased methylation of each CpG in
a time-dependent manner (Fig. 2F, G), in parallel with in-
creased p21 expression. Thus, even though EPA increased
p21 gene expression, it did notmodifymethylation on p21
CpG island V.
Figure 1. Effects of EPA on RH-7777 cell-cycle, viability, and p21 expression. A) G0/G1 cell-cycle distribution. Flow cytometry of
RH-7777 cells after 24 h treatment with OA (n) and EPA (s). Means 6 SD of 5 experiments are shown (*P , 0.01). B) Cell-cycle
distribution phases. Cells were treated with 100 mM fatty acids for 24 h. One of 5 experiments is shown as representative. C)
Effects of 100 mM fatty acid treatments on cell proliferation. Controls (white bars), OA (gray bars), and EPA (black bars). Means 6
SD of 5 experiments are shown (*P , 0.01). D) qRT-PCR shows p21 mRNA content in controls (white bars), OA (light gray bars),
EPA (black bars), and 5-aza (dark gray bars) after 100 mM fatty acids and 1 mM 5-aza. Means 6 SD of 3 experiments are shown
(*P , 0.05). E) Western blot analysis for p21 in controls (C) and after 100 mM OA and EPA and 1 mM 5-aza. One of
4 experiments is reported as representative. F) Western blot band density vs. untreated controls. Controls (white bars), OA (light
gray bars), EPA (black bars), and 5-aza (dark gray bars). Data are the means 6 SD of 4 experiments (*P , 0.05).
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EPA effects are TET1 dependent
As active cellular proliferation in liver cancer cells was
associated with 5hmC loss (31, 32), and EPA slowed cell-
cycle progression, we investigated 5hmC levels after EPA
conditioning. We chose dot-blot analyses using 5hmC
and 5mC antibodies on genomic DNA, as bisulfite-
pyrosequencing analysis does not discriminate between
5mC and 5hmC, which both are read as cytosines (33).
After 3, 24, and 48 h EPA treatment, 5hmC content
markedly increased (Fig. 3A, B), as confirmed by immu-
nofluorescence analyses, using the same antibody (Fig.
3C). No change in 5hmC was observed after OA
(Supplemental Fig. 1A, B). No significant differences in
5mC emerged after OA or EPA conditioning compared
with control cells (Supplemental Fig. 2A, B). Thus, EPA
increased 5hmC levels in genomic DNA without af-
fecting cellular 5mC. This apparent discrepancy may
be a result of the gap between 5hmC and 5mC levels in
cells and of low 5mC content in CpG islands compared
with cellular 5mC. In some enhancers, promoters, and
gene bodies that are in specific functional regions in the
genome, such as p21 island V, 5hmC was enriched,
suggesting that it played an active role in transcription
(12). The EPA-induced increase in 5hmCwas restricted
to these functional regions (e.g., CpG islands) that
Figure 2. Effects of EPA on the p21 gene CpG islands. A) p21 gene schema (21000/+8459). I, II, III, IV, and V indicate CpG
islands. B) Start exon 2 (red) and nucleotide sequence of CpG island V (bold), showing 18 CpG dinucleotides and 2 PPRE
variants (underlined). Italics refer to bisulfite sequencing primers and lowercase to ChIP, hMeDIP, and MeDIP primers. C)
Methyl-Profiler qPCR Primer Assay quantified p21 unmethylated DNA in all islands after 24 h 100 mM fatty acid treatment.
Controls (white bar), OA (light gray bar), and EPA (black bar). D) Bisulfite pyrosequencing of 5 CpG islands measured
methylation in 163 sites in controls. E) Island V-methylated (d) and -unmethylated (s) CpGs after bisulfite reaction on each
generated clone. F) Bisulfite pyrosequencing of each island V CpG after 100 mM OA and EPA and 1 mM 5-aza treatment.
Controls (white bars), 3 h (blue bars), 24 h (green bars), and 48 h (red bars). G) Bisulfite pyrosequencing showed total
methylation of island V. Controls (N) and after 100 mM OA (n) and EPA (s) and 1 mM 5-aza (,). Unless otherwise stated,
results are the means 6 SD of 3 experiments.
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Figure 3. EPA effects are TET1 dependent. A) Dot-blot analysis for 5hmC in controls and after 100 mM EPA. B) Dot-blot band
densities vs. controls. (*P , 0.05). DNA (150 ng; white bars) and 300 ng DNA (gray bars). C) 5hmC immunofluorescence for
controls and after EPA. Numbers refer to positive-stained nuclei. Original scale bars, 10 mm. D) hMeDIP and MeDIP of island V,
using 5hmC and 5mC antibodies. Controls (white bars), OA (gray bars), and EPA (black bars). E) Island V ChIP using RNAPII,
TET1, PPARg, and RXRa antibodies and the same primers as the hMeDIP and MeDIP assays. Controls (white bars), OA (gray
bars), and EPA (black bars). F) PPARg interacted with TET1 and RXRa. PPARg was immunoprecipitated using PPARg antibody
from nuclear extract of controls after 3 h EPA. Co-IP TET1 and RXRa were detected by Western blot (WB). Unless otherwise
stated, results are the means 6 SD of 3 experiments.
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constitute specific DNA portions, whereas in total
DNA, 5mC was stably conserved. Increased 5hmC
levels (Fig. 3A, B) constituted a very small part of the
total 5mC, which was distributed across the entire
DNA spectrum. To investigate whether 5hmC was
present on the p21 island V, we used an hMeDIP as-
say with the 5hmC antibody. qRT-PCR amplifica-
tion of island V, containing 18 CpG dinucleotides, was
obtained from IP DNA. After 3 h EPA treatment, the
hMeDIP assay revealed significant anti-5hmC binding
to p21 island V, which remained stable for up to 48 h
(Fig. 3D), suggesting that 5hmChas a role to play in p21
expression. The MeDIP assay demonstrated that EPA
converted 5mC to 5hmC on island V, in line with the
increase in 5hmC binding (Fig. 3D).
We next investigated whether the EPA-induced in-
crease in 5hmC on island V underlay increased p21 ex-
pression. ChIP analysis on controls and 3 h after OA and
EPA treatments showed significant anti-RNAPII binding
to island V, which persisted for up to 48 h, only after EPA
treatment (Fig. 3E). 5hmC enrichment overlapped with
active p21 transcription, in agreement with increased p21
mRNA and protein levels.
We next investigatedwhether TET1, TET2, and TET3
proteins (34) were involved in the conversion of 5mC to
5hmC. Western blot analyses found no differences in
TET proteins expression after OA and EPA treatments
(Supplemental Fig. 3A). In contrast, the ChIP assay,
using TET isoform antibodies, detected very high TET1
enrichment on island V of the p21 gene, only after EPA
(Fig. 3E). TET2 and TET3 exhibited no detectable
binding after OA and EPA (data not shown). TET1
binding persisted for up to 48 h, maintaining a hypo-
methylated status, which inhibitedDNMT activity (35).
These data suggest that only the TET1 isoform was in-
volved in increased 5hmC on island V and that EPA
induced its activitywithout affecting its expression. The
key role of TET1 activity was further evaluated by
immunofluorescence analyses for 5hmC in DMOG-
treated cells, as DMOG is a small molecule inhibitor of
TET activity. No difference in 5hmC signal levels was
observed between control and DMOG-treated cells.
After DMOG, EPA treatment did not increase TET1
activity (Supplemental Fig. 3B).
To understand how EPA promoted TET1 binding on
island V, we considered the following: 1) fatty acids, such
as EPA and fatty acid-derived eicosanoids, are natural
PPARg ligands (36), and 2) PPARg promotes 5hmC pro-
duction around the PPRE by recruiting TET1 during adi-
pocyte differentiation (37).
Aswe had found 2 PPRE variants on islandV (Fig. 2B),
we performed ChIP analyses using the PPARg and RXRa
antibodies, as both receptors form an active heterodimer
after bindingwith their ligands (38). Interestingly, after 3 h
EPA treatment, both displayed significant binding to
island V, which gradually dropped at 48 h (Fig. 3E).
Western blot analyses showed no differences in PPARg
and RXRa protein levels after EPA treatment (Supple-
mental Fig. 3). Overall, EPA induced TET1, PPARg, and
RXRaproteins binding to islandVof thep21 genewithout
affecting their expression.
EPA promoted assembly of a TET1-PPARg-RXRa
protein complex
To demonstrate that TET1 physically interacted with
PPARg after 3 h EPA conditioning, we performed a co-IP
assay using the PPARg antibody in a nuclear extract of
EPA-treated cells. With the use of TET1 and RXRa anti-
bodies, Western blot analyses showed that both bound
PPARg (Fig. 3F). Thus, a TET1-PPARg-RXRa protein
complex appears to be essential for recruiting TET1 to
island V.
ThePLA,which investigates direct protein interactions,
provided further proof of TET1-PPARg binding and ex-
cluded TET1-RXRa binding after 3 h EPA conditioning.
Spots highlighting the TET1-PPARg interaction decreased
within 48 h (Fig. 4A), supporting ChIP assay evidence of
PPARg release from island V (Fig. 3E). No spot for TET1-
RXRawas foundat any timepoint (Supplemental Fig. 4B),
confirming TET1-PPARg-binding specificity in the co-IP
assay. A PLA using PPARg and RXRa antibodies con-
firmed that the 2 nuclear receptors formed a heterodimer,
interacting physically after 3 h EPA conditioning. Spots
dropped in number within 48 h, suggesting heterodimer
binding gradually decreased, probably as the bond de-
tached from its ligand (Supplemental Fig. 4A). Fatty acids
and their eicosanoid derivatives are natural ligands of
PPARg andRXRa (39, 40). APLAusing the EPAantibody
and either the PPARg or RXRa antibody revealed that
EPA bound both PPARg and RXRa, leading to hetero-
dimer formation.EPA-PPARg (Fig. 4B) orEPA-RXRa (Fig.
4C) bindingwas significantly high after 3 h EPA exposure,
decreased at 24 h, and disappeared at 48 h. These obser-
vations suggested that at 48 h, EPA separates from the
2 receptors, thus breakingup the active heterodimer (Fig. 5).
This molecular mechanism coincides with kinetic pro-
files of PPARg and RXRa on island V, observed by the
ChIP assay, and excludes a role for an EPA eicosanoid
metabolic derivative.
DISCUSSION
This study demonstrated that EPA induces DNA deme-
thylation in HCCs. It simultaneously binds PPARg and
RXRa to assemble aTET1-PPARg-RXRaprotein complex,
which associates with hypermethylated DNA regions,
where TET1 enriches 5hmC. In fact, the;6-fold 5hmCrise
in genomic DNA confirmed that the cells accumulate
5hmC as a stable modification (41). The 5hmC increase on
p21 island V, which was observed after 3 h, was the EPA-
induced starting change. It enhanced p21 expression,
which after 24 h, inhibited cell-cycle progression and cell
proliferation. Our observations showed that 5hmC,
the first TET1 product in its oxidation chain reaction,
remained stable for up to 48 h in DNA. As a conse-
quence, TET1 appeared unable to promote the con-
secutive oxidation reactions for transforming 5hmC to
5-formylcytosine and 5-carboxylcytosine. No information
is, at present, available on the mechanisms of TET1 action
when it catalyzes thewhole sequential oxidation reactions
instead of stably stopping at 5hmC. This crucial topic
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requires further investigation in both normal and tumor
cells with different phenotypes.
Our results suggest that 5hmC played a functional role
in activating transcription. Indeed,we found that in island
V, 5hmC rather than 5mC, induced p21 expression in line
with the increase in RNAPII binding. Evidence in support
of these data derives from experimental models showing
that increased 5hmC levels were associated with active
transcription (12, 42) and were found on transcription
factor-binding sites, enhancers, promoters, and exons in
actively expressedgenes (43), similar toour findingson the
p21 exon 2 island V.
In adipocyte differentiation, the PPARg-TET1 interac-
tion has previously been reported to produce local 5hmC
Figure 4. PLA showed TET1/
PPARg (A), EPA/PPARg (B),
and EPA/RXRa (C) interac-
tions after EPA. Red spots show
a single interaction. DNA coun-
terstaining with DAPI. Merge
images show nuclear localiza-
tion. Original scale bars, 10 mm.
Data are the means 6 SD of
3 experiments.
EPA INCREASES 5hmC LEVELS THROUGH A TET1-PPARg-RXRa PROTEIN COMPLEX 9
Downloaded from www.fasebj.org by San Francisco State Univ J Paul Leonard Library (130.212.18.96) on July 30, 2018. The FASEB Journal Vol. ${article.issue.getVolume()}, No. ${article.issue.getIssueNumber()}, primary_article.
after several days (37). As we found that 5hmC increases
within a few hours of EPA treatment, we speculate that
molecular mechanisms could vary with cell phenotypes
(i.e., adipocytes vs. tumor cells).Alternatively, our findings
suggest that a simultaneous EPA binding to PPARg and
RXRamight modify the kinetics of the effect, which may
be different when EPA binds singularly to PPARg or
RXRa.
As simultaneous bindingof bothPPARg andRXRahas
never before been described for EPA or other ligands, the
possibility exists that other n-3 PUFAs or 3-series eicosa-
noid derivatives may exhibit a similar action, as they are
potential ligands for PPARg and RXRa (36, 40) and in-
hibit proliferation in cancer cellswith a similarmechanism
(20, 21).
Our experiments provided the first evidence that the
PPARg-RXRa heterodimer functioned as a shuttle. It
recruited TET1 to island V and then subsequently exited
the DNA, leaving TET1 bound to island V (Fig. 5). TET1
maintained the DNA hypomethylated status, probably
facilitating gene expression, as previously proposed (35).
Indeed, TET1 prefers binding hypomethylated high CpG-
dense regions to prevent DNMTactivity and inhibit DNA
methylation (44).
The increase in 5hmC in the island V p21 gene was
likely a result of specific PPARg-RXRa binding to 2 PPRE
variants. Alternatively, the PPARg-RXRa heterodimer
might function simply as a shuttle without binding to the
PPRE. To explain the mechanism underlying the increase
in 5hmC in whole DNA after EPA treatment, one might
speculate that in genome areas different from island V of
the p21 gene, where PPREs are not found, PPARg may
bind toother consensus sequences, actingas amonomeror
homodimer (45) to recruit TET1.
The increased TET1 activity could be synergistic with
TET1 expression upregulation. In fact, as TET1 re-
expression opposes cell progression, it is recognized as a
tumor-suppressor gene (46). Its downregulation or si-
lencing promoted malignancy and increased cellular
proliferation (47) and may be directly mediated by CpG
methylation in multiple human tumor cells (48). Thus,
TET1-mediatedDNAhydroxymethylationmay be a key
player in tumor growth (46).
In summary, our findings demonstrated that EPA-
related anti-tumor proliferation (49) was a result of a
TET1-dependent DNA demethylation process. EPA con-
ditioning reduced tumor cell proliferation, possibly by
counteracting the decrease in 5hmC and TET1 down-
regulation, associated with HCC progression (31).
Besides EPA, a-linolenic acid, and docosahexaenoic
acid, the other well-known n-3 PUFAs were reported to
exert beneficial effects on cancer cells and in chronic dis-
eases, such as insulin resistance and cardiovascular dis-
ease (50, 51), which are strongly related to abnormal DNA
methylation (52, 53). If individual n-3 PUFAs, which are
used generally as a mixture, exhibit the same epigenetic
action as EPA, then they may also act as demethylating
agents. Much work needs to be carried out to test this
hypothesis, especially in vivo in physiologic and patho-
logic conditions. Therefore, present results are the poten-
tial starting point for assessing the role of EPA at
pharmacological doses in clinical trials.More importantly,
they pave the way for the study of PUFA-related DNA
demethylation in cancer and other diseases with aberrant
DNAmethylation.
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